Athenex, Inc. (ATNX) Just Recorded A Sigfniciant Increase

February 15, 2018 - By Marie Mckinney

The stock of Athenex, Inc. (NASDAQ:ATNX) is a huge mover today! The stock increased 6.65% or $1.04 during the last trading session, reaching $16.69. About 525,019 shares traded or 48.24% up from the average. Athenex, Inc. (NASDAQ:ATNX) has 0.00% since February 15, 2017 and is . It has underperformed by 16.70% the S&P500.
The move comes after 9 months positive chart setup for the $1.04 billion company. It was reported on Feb, 15 by We have $17.19 PT which if reached, will make NASDAQ:ATNX worth $31.20M more.

More notable recent Athenex, Inc. (NASDAQ:ATNX) news were published by: which released: “Athenex, Inc. Announces Pricing of Initial Public Offering” on June 14, 2017, also with their article: “Athenex, Inc. Added to Nasdaq Biotechnology Index” published on December 18, 2017, published: “Athenex Announces Chinese FDA Allowance of Investigational New Drug …” on January 08, 2018. More interesting news about Athenex, Inc. (NASDAQ:ATNX) were released by: and their article: “Athenex Inc.” published on June 14, 2017 as well as‘s news article titled: “Athenex, Inc. Announces Proposed Offering of Common Stock” with publication date: January 22, 2018.

Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of cancer. The company has market cap of $1.04 billion. The Company’s Orascovery product candidates include Oraxol, an oral dosage form, which is in a Phase III trial in metastatic breast cancer for the treatment of advanced gastric cancer; Oratecan, an anticancer agent that is in a Phase 1 study for the treatment of colorectal, lung, ovarian, cervical, pancreatic, upper gastrointestinal, and brain cancer; Oradoxel, an anticancer agent, which is in a Phase 1 clinical study in the treatment of breast, prostate, gastric, head and neck, and lung cancer; and Oratopo, an anticancer for the treatment of cervical, ovarian ,and lung cancer. It currently has negative earnings. The firm also develops KX-01, a compound, which is in Phase 3 study for the treatment of for actinic keratosis; and KX-02 for the treatment of gliomas.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.